Tapentadol
- Generic Name
- Tapentadol
- Brand Names
- Nucynta
- Drug Type
- Small Molecule
- Chemical Formula
- C14H23NO
- CAS Number
- 175591-23-8
- Unique Ingredient Identifier
- H8A007M585
- Background
Tapentadol is a centrally-acting synthetic analgesic with a dual mechanism of action. It is a mu-opioid receptor agonist that also inhibits norepinephrine reuptake.
Tapentadol was first approved by the FDA on November 20, 2008. The extended-release formulation of tapentadol was also approved by the FDA on August 26, 2011. Used in the management of pain, tapentadol is typically reserved for patients who have limited alternative treatment options.
- Indication
用于治疗严重到需要阿片类镇痛剂且替代治疗不充分的急性疼痛。
- Associated Conditions
- Diabetic Peripheral Neuropathic Pain (DPN), Severe Acute Pain, Severe Pain
- Associated Therapies
- -
Diabetic Peripheral Neuropathy Treatment Market 2034
Diabetic Peripheral Neuropathy market to surge due to increasing prevalence and awareness, with multiple-stage pipeline products revolutionizing market dynamics. Key companies include Grünenthal, Averitas Pharma, Daiichi Sankyo, Vertex Pharmaceuticals, Helixmith, and Lexicon Pharmaceuticals. Emerging therapies such as QUTENZA (capsaicin) and TARLIGE (mirogabalin besylate) are expected to drive market growth.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath